Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collabor...
Full description
Bibliographic Details
| Main Authors: |
S. G. P. Funnell,
W. E. Dowling,
C. Muñoz-Fontela,
P.-S. Gsell,
D. E. Ingber,
G. A. Hamilton,
L. Delang,
J. Rocha-Pereira,
S. Kaptein,
K. H. Dallmeier,
J. Neyts,
K. Rosenke,
E. de Wit,
H. Feldmann,
P. Maisonnasse,
R. Le Grand,
M. B. Frieman,
C. M. Coleman |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Publishing Group
2020-08-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-020-17907-w
|
|---|
